Etoposide treatment in secondary hemophagocytic syndrome: impact on healthcare-associated infections and survival

BACKGROUND: Etoposide remains the cornerstone of symptomatic management of critically ill patients with secondary hemophagocytic syndrome (sHS). Risk of healthcare-associated infections (HAIs) in this setting with etoposide has never been assessed. We sought to evaluate the association between etopo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupont, Thibault, Darmon, Michael, Mariotte, Eric, Lemiale, Virginie, Fadlallah, Jehane, Mirouse, Adrien, Zafrani, Lara, Azoulay, Elie, Valade, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616615/
https://www.ncbi.nlm.nih.gov/pubmed/36307626
http://dx.doi.org/10.1186/s13613-022-01075-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616615/
https://www.ncbi.nlm.nih.gov/pubmed/36307626
http://dx.doi.org/10.1186/s13613-022-01075-9

Ejemplares similares